✦ LIBER ✦

Second- and Third-generation Aromatase Inhibitors as First-line Endocrine Therapy in Postmenopausal Metastatic Breast Cancer Patients: A Pooled Analysis of the Randomised Trials

✍ Scribed by Elledge, R.M.

Book ID: 122859690
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 94 KB
Volume: 18
Category: Article
ISSN: 1043-321X
DOI: 10.1016/S1043-321X(07)80092-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

New aromatase inhibitors as second-line

New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma : A pooled analysis of the randomized trials

✍ Paolo Carlini; Emilio Bria; Diana Giannarelli; Gianluigi Ferretti; Alessandra Fe 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 2 views

An open randomised trial of second-line

An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole

✍ J.S Tobias; A Howell 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 122 KB

An open randomised trial of second-line

An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole

✍ C. Rose; O. Vtoraya; A. Pluzanska; N. Davidson; M. Gershanovich; R. Thomas; S. J 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 213 KB

A comparison of fulvestrant and the thir

A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer

✍ David Dodwell; Ignace Vergote 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 317 KB

68. Randomized trial between the selecti

68. Randomized trial between the selective aromatase inhibitor formestane (Lentaron) or tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer: confirmation of bioequivalence in survival

✍ C.M. Royce; L. Mauriac; R. Pérez Carrion; V. Alberola; F. Calabresi; R.Th. Miche 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 148 KB

A phase II trial of a selective c-Met in

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

✍ Kang, Yoon-Koo; Muro, Kei; Ryu, Min-Hee; Yasui, Hirofumi; Nishina, Tomohiro; Ryo 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 234 KB